Anemia Treatment Gains FDA Approval; Biotech Company Acceleron Pops – Investor’s Business Daily

Shares of Acceleron Pharma (XLRN) popped Friday after the biotech company gained Food and Drug Administration approval for a Celgene (CELG)-partnered anemia treatment.
XOn the stock market today, Acceleron stock jumped 6.6%, to 43.28, in above-average volume…

Click here to view the original article.